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Summary
Some comorbidities, such as hypertension, are associated with higher von
Willebrand factor (VWF) levels in the general population. No studies have
been conducted to assess this association in patients with von Willebrand
disease (VWD). Therefore, we studied this association in patients with type
1 (n = 333) and type 2 (n = 203) VWD from the ‘WiN” study. VWF anti-
gen (VWF:Ag) was higher in type 1 VWD patients with hypertension [dif-
ference: 023 iu/ml, 95% confidence interval (CI): 011–035], diabetes
mellitus (011 iu/ml, 95% CI: 002 to 023), cancer (014 iu/ml, 95% CI:
003–025) and thyroid dysfunction (014 iu/ml, 95% CI: 003–026) than
in patients without these comorbidities (all corrected for age, sex and blood
group). Similar results were observed for VWF collagen binding capacity
(VWF:CB), VWF activity as measured by the VWF monoclonal antibody
assay (VWF:Ab) and factor VIII (FVIII) coagulant activity (FVIII:C). In
type 1 VWD, age was associated with higher VWF:Ag (003 iu/ml; 95% CI:
001–004), VWF:CB (002 iu/ml; 95% CI: 000–004), VWF:Ab (004 iu/
ml; 95% CI: 002–006) and FVIII:C (003 iu/ml; 95% CI: 001–006) per
decade increase. After adjustment for relevant comorbidities, these associa-
tions were no longer significant. Despite the higher VWF and FVIII levels,
type 1 VWD patients with comorbidities had more bleeding episodes, par-
ticularly during surgery. There was no association between comorbidities
and VWF/FVIII levels or bleeding phenotype in type 2 VWD patients. In
conclusion, comorbidities are associated with higher VWF and FVIII levels
in type 1 VWD and may explain the age-related increase of VWF and FVIII
levels.
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Von Willebrand disease (VWD) is the most common inher-
ited bleeding disorder, and is characterized by mucocuta-
neous bleeding due to a deficiency of von Willebrand Factor
(VWF) (Leebeek & Eikenboom, 2016). VWD can be caused
by reduced levels (type 1), abnormal function (type 2) or
complete absence (type 3) of VWF (Sadler et al, 2006).
VWF levels have a large inter- and intra-individual vari-
ability (de Maat et al, 2016). The inter-individual variability
is mostly caused by genetic variations and blood group, while
the intra-individual variability is mainly caused by environ-
mental factors (Gill et al, 1987; Jenkins & O’Donnell, 2006;
van Schie et al, 2011). Furthermore, an age-related increase
of VWF levels has been observed in both healthy individuals
and patients with type 1 VWD (Gill et al, 1987; Coppola
et al, 2003; Tofler et al, 2005; Vischer et al, 2005; Sanders
et al, 2014; Rydz et al, 2015; Albanez et al, 2016). Both in
healthy individuals and patients with VWD, higher levels of
VWF are observed after exercise, trauma or surgery and dur-
ing infectious diseases, pregnancy or use of certain medica-
tion (Prentice et al, 1972; Clark et al, 1998; Sadler et al,
2000; James & Lillicrap, 2012; Kawecki et al, 2017). In indi-
viduals without VWD increase of VWF has been associated
with several disorders, including hypertension, diabetes melli-
tus and hypercholesterolaemia (Conlan et al, 1993; Kessler
et al, 1998; Seligman et al, 2000; Brunner et al, 2005). Fur-
thermore, several studies have demonstrated increased VWF
levels in patients with cancer, hyperthyroidism, chronic liver
disease and renal failure (Danielsson et al, 1990; Liu et al,
1993; Holvoet et al, 1996; Auwerda et al, 2005, 2007; Fran-
chini et al, 2013; Elbers et al, 2016; Leebeek, 2016).
Although VWF levels are altered in patients with the
above-mentioned disorders, the association between these
disorders and VWF levels in patients with VWD is unknown.
Also, the relationship between comorbidities, mostly occur-
ring at older age, and the age-related increase of VWF levels
is unknown.
Therefore, our primary aim was to assess the association
between comorbidities and VWF and factor VIII (FVIII)
levels in patients with VWD type 1 and 2. The second aim
was to study whether comorbidities can explain the previ-
ously reported age-related increase of VWF in VWD type 1
patients. Thirdly, we aimed to assess the association between
comorbidities and the bleeding phenotype of VWD patients.
Materials and methods
Participants
We performed a nationwide cross-sectional study in patients
with VWD in the Netherlands; the “Willebrand in the
Netherlands” (WiN) study (de Wee et al, 2010, 2012).
Patients with VWD were recruited between October 2007
and October 2009. The inclusion criteria were haemorrhagic
symptoms or a family history of VWD, and historically low-
est VWF antigen (VWF:Ag) and/or VWF ristocetin cofactor
activity (VWF:RCo) ≤030 iu/ml and/or FVIII coagulant
activity levels (FVIII:C) ≤040 iu/ml (for type 2N VWD).
Patients were excluded if they had other haemostatic
disorders. Blood and saliva samples were obtained at study
inclusion.
For the current analyses, we excluded patients with type 3
VWD (defined as VWF levels <005 iu/ml and VWF propep-
tide (VWFpp) <005 iu/ml), because by definition there will
be no increase of VWF levels in these patients (Sanders et al,
2015a). Furthermore, we excluded patients younger than
16 years old, patients with missing data on comorbidities,
patients without centrally measured VWF levels or with cen-
trally measured VWF levels during pregnancy, or desmo-
pressin medication or clotting factor concentrate infusion
72 h prior to blood sampling. The study was performed
according to the Declaration of Helsinki and approved by
the Medical Ethical Committees of all participating centres.
Informed consent was signed by all patients.
Assessment methods
The assessment methods used in the WiN study, have been
described in detail previously (de Wee et al, 2010, 2012).
Participants completed an extensive questionnaire, including
questions on comorbidities, use of medication, self-adminis-
tered version of the condensed Tosetto bleeding score and
bleeding episodes that required haemostatic treatment in the
year prior to inclusion (Tosetto et al, 2006; Bowman et al,
2008). We previously reported that the self-administered
bleeding score is comparable to the expert-administered
bleeding score (de Wee et al, 2012). We did not score for
bleeding if patients received treatment prophylactically, for
instance before surgery (Tosetto et al, 2008).
Definitions
Presence of comorbidities was assessed at study inclusion,
immediately before blood drawing for VWF level measure-
ments. As the aim of the study was to assess the effect of
comorbidities on VWF and FVIII levels, we only focused on
comorbidities that are known to have an association with
VWF or FVIII levels according to the literature. First, we
analysed the effect of individual comorbidities on VWF and
FVIII levels. All the disorders that seemed to be associated
with higher VWF or FVIII levels in our VWD population
were defined as relevant comorbidities. Secondly, we assessed
the association between relevant comorbidities (as a group)
and the age-related increase of VWF and FVIII levels in
patients with type 1 VWD.
Patients were defined as having diabetes mellitus or thy-
roid dysfunction if reported on the questionnaire, or if they
used medication that could only be used for these disorders,
such as insulin, metformin or levothyroxine. We defined
patients as having cancer when they reported to have a
malignant disease. We did not define basal cell carcinoma as
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cancer, because of the non-metastatic, semi-malignant char-
acteristics (Bauer et al, 2015). Patients were defined as having
hypertension or hypercholesterolaemia if reported on the
questionnaire. Arterial thrombotic events were defined as a
medical history of myocardial infarction, ischaemic stroke,
transient ischaemic attack (TIA) or angina pectoris. These
thrombotic events were previously evaluated by studying the
medical charts of these patients (Sanders et al, 2013). We
defined renal disease as intrinsic renal diseases, a renal trans-
plantation in the past or a kidney removal due to an anom-
aly. Liver disease was defined as intrinsic liver diseases such
as hepatitis or cirrhosis.
Laboratory measurements
At inclusion in the study, plasma levels of VWF:Ag, VWF col-
lagen binding capacity (VWF:CB), VWF activity (measured by
the VWF monoclonal antibody assay; VWF:Ab) and FVIII
coagulant activity (FVIII:C) were centrally measured at the
Erasmus University Medical Centre. VWFpp was centrally
measured at the Leiden University Medical Centre (Leiden, the
Netherlands) (Sanders et al, 2015a). We previously reported
detailed information on blood sampling procedure and labora-
tory measurements (de Wee et al, 2012; Sanders et al, 2015a).
VWF:Ag and VWF:CB were measured with an in-house
enzyme-linked immunosorbent assay. For VWF:Ag we used
polyclonal rabbit anti-human VWF antibodies and horseradish
peroxidase conjugated anti-human VWF antibodies
(DakoCytomation, Glostrup, Denkmark) for detection, while
for VWF:CB we used collagen type 1 (Sigma-Aldrich, St Louis,
MO, USA) for capture and horseradish peroxidase (HRP)-
conjugated anti-human VWF antibodies (DakoCytomation)
for detection. VWF:Ab was assessed with a latex immune assay
on an automated coagulometer, in which monoclonal anti-
bodies against the GP1ba binding site of VWF was used,
reflecting the binding activity of VWF to GP1ba (HemosILTM
von Willebrand Factor Activity; Instrumentation Laboratory
BV, Breda, the Netherlands) (Sanders et al, 2015a). The VWF
antibody assay was more recently suggested to be called VWF:
Ab by the VWF subcommittee of the Scientific and Standard-
ization Committee of the International Society for Thrombosis
and Haemostasis (Bodo et al, 2015). Therefore, we have used
VWF:Ab throughout the manuscript. We measured FVIII:C
using a one-stage clotting assay (TriniCLOT, Biomerieux,
Marcy l’Etoile, France) with FVIII-deficient plasma (Biopool,
Umea, Sweden) and reference plasma (Precision biologic, Kor-
dia, Leiden, the Netherlands).
Statistical methods
Categorical data are presented as frequencies and propor-
tions. Continuous data are presented as median and
interquartile range (IQR) or mean and (standard deviation).
As type 1 and type 2 VWD have different mechanisms of dis-
ease pathogenesis, we analysed each separately.
VWF, FVIII and bleeding score were not normally dis-
tributed. However, the variables fulfilled the assumptions of
linearity and homoscedasticity, whereas the sample size was
large. Therefore, we used multiple regression analyses to
calculate the effect of comorbidities on VWF and FVIII
levels and bleeding score. For all comorbidities multiple
regression analyses were adjusted for age, sex and blood
group. The effect of an individual comorbidity on VWF
levels was only adjusted for other comorbidities when the
other comorbidities were relevant confounders (i.e. when
addition of the other comorbidity to the regression model
caused at least 10% change in the regression coefficient).
For each of the disorders; hypertension, diabetes, arterial
thrombotic events and hypercholesterolaemia, the other
three disorders were analysed to identify whether they were
confounders or effect modifiers. For hypertension and
hypercholesterolaemia, we additionally investigated whether
the use of anti-hypertensive drugs and statins acted as con-
founders or effect modifiers.
In the multiple regression models for analysing the associ-
ation between comorbidities and the bleeding score, we
adjusted for age, sex and blood group. We report linear
regression outcomes as unstandardized b coefficient (differ-
ence) followed by the 95% confidence interval (CI). A
P-value less than 005 was defined as significant. Statistical
analyses were performed using SPSS Statistics version 24
(IBM Corp., Armonk, NY, USA).
Results
We included 536 patients in this study from the total WiN-
study population of 837 patients. Figure 1 shows a consort
diagram illustrating patient inclusion. Most patients were
female (64%), had blood group O (62%) and had type 1
VWD (62%) (Table I). The mean age in type 1 and type 2
VWD were 47 (SD 15, range 17–81) and 46 (SD 16, range
16–83) years, respectively. Comorbidities were reported in
175 patients (33%), of whom 47 patients had two comor-
bidities, 19 patients had three comorbidities and 2 patients
had four comorbidities. The most frequent reported comor-
bidity was hypertension (218%), followed by hypercholes-
terolaemia (95%) (Table II).
837 Patients
173 < 16 years old
13 Missing data on comorbidities
93 No centrally measured 
levels available
22 Type 3 VWD
536 VWD patients
Fig 1. Consort diagram illustrating patient inclusion in the study.
VWD, von Willebrand disease.
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Hypertension
There were 117 patients (22%) with hypertension (Table II).
Patients with hypertension were older and more often female
(Table II). Ninety seven of the 117 patients (83%) used anti-
hypertensive drugs.
Type 1 VWD patients with hypertension had higher VWF:
Ag, VWF:CB, VWF:Ab and FVIII:C, with a difference of
respectively 023 iu/ml (95% CI: 011–035), 024 iu/ml (95%
CI: 008–039), 026 iu/ml (95% CI: 009–044) and 019 iu/
ml (95% CI: 003–035) when compared to patients without
hypertension (corrected at least for age, sex, blood group and
anti-hypertensive treatment, Fig 2). These findings were
observed in both young (<65 years) and elderly (≥65 years)
VWD patients, although we did not find a significant out-
come in elderly type 1 VWD patients, due to the small num-
ber of patients (Figure S1). In patients with type 1 VWD and
hypertension, use of anti-hypertensive drugs was associated
with lower VWF:Ag, 018 iu/ml (95% CI: 033 to 003),
and tended to be associated with lower VWF:Ab, 021 iu/
ml (95% CI: 043 to 000) (both corrected for age, sex and
blood group). In patients with type 2 VWD, no association
between hypertension or use of anti-hypertensive drugs and
VWF or FVIII levels was found (Fig 2; Table SI).
Diabetes mellitus
Twenty VWD patients (37%) had diabetes mellitus at the
time of inclusion in the WiN study. Patients with diabetes
were older and were less often blood group O compared to
patients without diabetes (Table II). Fourteen patients had
type 2 diabetes; the type of diabetes was not reported in the
other six patients.
Type 1 VWD patients with diabetes had higher VWF:Ab
and FVIII:C compared to patients without diabetes, with a
difference of 023 iu/ml (95% CI: 005–040) and 027 iu/ml
(95% CI: 011–044), respectively. A similar association,
although not significant, was observed for VWF:Ag and
VWF:CB, respectively 011 iu/ml (95% CI: 002 to 023)
and 015 iu/ml (95% CI: 001 to 031) (Fig 3). In patients
with type 2 VWD no association between diabetes and VWF
or FVIII levels was found (Fig 3; Table SI).
Cancer
Twenty-three VWD patients (43%) had cancer at inclusion
in the study; these patients were generally older (Table II).
Prostate cancer was the most common form of cancer,
occurring in five patients, followed by breast cancer in four
patients.
Type 1 VWD patients with cancer had higher VWF:Ag
and VWF:Ab, with a difference of 014 iu/ml (95% CI: 003–
025) and 019 iu/ml (95% CI: 003–035), respectively. A
similar trend was seen for VWF:CB and FVIII:C in cancer
patients, respectively: 014 iu/ml (95% CI: 001 to 029)
and 014 iu/ml (95% CI: 002 to 030) (Fig 4; Table SI).
Patients with type 2 VWD tended to have a FVIII:C of
016 iu/ml (95% CI: 001 to 032) higher compared to type
2 VWD patients without cancer. However, this could be
attributed to one patient who had a FVIII:C of 176 iu/ml
(Fig 4).
Thyroid dysfunction
Five patients (09%) had hyperthyroidism and 13 patients
(24%) had hypothyroidism at inclusion in the WiN study.
Patients with hyperthyroidism and hypothyroidism were sig-
nificantly older than patients without these disorders
(Table II). All patients with hypothyroidism used thyroid-sti-
mulating hormones (levothyroxine). The analyses for both
disorders were only performed in patients with type 1 VWD,
due to the low number of patients in type 2 VWD
(Table II).
VWF:CB and VWF:Ab tended to be higher in patients
with type 1 VWD with hyperthyroidism, although this was
not significant, than in patients without hyperthyroidism,
with a difference of 021 iu/ml (95% CI: 004 to 047) and
027 iu/ml (95% CI: 001 to 054), respectively (Fig 5;







Age (years), mean (SD) 47 (15) 46 (16) 46 (15)
Female, n (%) 232 (70%)* 113 (56%)* 345 (64%)
Blood group O, n (%) 227 (68%)* 105 (52%)* 332 (62%)
VWF:Ag 039 [025–055]* 025 [016–035]* 031 [021–047]
VWF:CB 045 [026–068]* 008 [006–015]* 027 [010–054]
VWF:Ab 048 [026–072]* 008 [004–016]* 025 [011–057]
FVIII:C 068 [052–089]* 038 [027–049]* 054 [037–077]
Bleeding score 9 [5–15]* 12 [8–17]* 11 [6–16]
Data are presented as median [interquartile ranges], unless otherwise specified. FVIII:C, factor VIII coagulant activity; SD, standard deviation;
VWD, von Willebrand disease; VWF:Ab, von Willebrand factor activity as measured by a monoclonal antibody assay; VWF:Ag; von Willebrand
factor antigen; VWF:CB, von Willebrand factor collagen binding capacity.
*P < 005 comparing patients with type 1 and type 2 VWD.
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Table SI). Remarkably, type 1 VWD patients with hypothy-
roidism also had higher FVIII:C [020 iu/ml (95% CI: 001–
040)], and tended to have higher VWF:Ab [018 iu/ml (95%
CI: 002 to 038)] (Fig 5).
Arterial thrombotic events and hypercholesterolaemia
Twenty-three patients (43%) had previously suffered an
arterial thrombotic event at the time of inclusion in the WiN
study. Fifty-one patients (95%) were reported to have hyper-
cholesterolaemia. Detailed information on the type of arterial
thrombotic events in our study population was reported pre-
viously (Sanders et al, 2013). Of the patients with hyperc-
holesterolaemia, 27 (53%) used statins at the time of
inclusion. Patients with arterial thrombotic events and
hypercholesterolaemia were older than patients without
these conditions (Table II). No association was found
between prevalent arterial thrombotic events, hypercholes-
terolaemia or use of statins and VWF or FVIII levels (data
not shown).
Liver- and renal disease
Chronic liver disease was present in ten VWD patients
(19%) and renal disease was present in four patients (07%)
at inclusion in the study (Table II). Because of the small
number of patients we could only analyse patients with type
2 VWD with chronic liver disease. In this group, three
patients had hepatitis B and five patients hepatitis C. Type 2
VWD patients with liver disease did not have different VWF













Total 536 117 20 23 5 13 23 51 10
Type 1, n (%) 333 (62%) 75 (64%) 14 (70%) 15 (65%) 5 (100%) 10 (77%) 14 (61%) 32 (63%) 2 (20%)
Type 2, n (%) 203 (38%) 42 (36%) 6 (30%) 8 (35%) 0 (0%) 3 (23%) 9 (39%) 19 (37%) 8 (80%)
Age, years 46 (15) 59* (10) 60* (12) 57* (13) 59* (4) 61* (12) 61* (12) 58* (12) 48 (16)
Female, n (%) 345 (64%) 90* (77%) 12 (60%) 13 (57%) 5 (100%) 11 (85%) 12 (52%) 36 (71%) 5 (50%)
Blood group O, n (%) 332 (62%) 73 (62%) 8* (40%) 14 (61%) 2 (40%) 9 (75%) 14 (61%) 33 (65%) 4 (40%)
Data are presented as mean (standard deviation), unless otherwise specified. ATEs, arterial thrombotic events; DM, diabetes mellitus.
*P < 005 comparing patients with and without the mentioned disorder.
Fig 2. The association between hypertension and VWF and FVIII. Number of patients with and without hypertension are respectively in type 1:
n = 75 vs. n = 255, type 2: n = 42 vs. n = 160. Multiple regression outcomes in type 1 VWD corrected for; age, sex, blood group and anti-hyper-
tensive treatment. VWF:Ab and FVIII:C additionally corrected for diabetes. Multiple regression outcomes in type 2 VWD corrected for; age, sex,
blood group and anti-hypertensive treatment. VWF:Ag, VWF:CB and FVIII:C additionally corrected for hypercholesterolaemia. Moreover, FVIII:
C also corrected for arterial thrombotic events. The association between hypertension and VWF levels was only adjusted for other comorbidities
when the other comorbidities were relevant confounders (see methods). Data presented as boxplots with median and interquartile ranges, and 5–
95 percentiles. *P < 005. **P < 001. ***P < 0001. FVIII:C, factor VIII coagulant activity; ns, not significant; VWD, von Willebrand disease;
VWF:Ab, von Willebrand factor activity as measured by a monoclonal antibody assay; VWF:Ag; von Willebrand factor antigen; VWF:CB, von
Willebrand factor collagen binding capacity.
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or FVIII levels compared to type 2 patients without liver dis-
ease (data not shown).
The association between the number of comorbidities and
VWF and FVIII levels
All comorbidities that had an association with higher VWF
and FVIII levels were defined as relevant comorbidities:
hypertension, diabetes mellitus, cancer and thyroid dysfunc-
tion. Patients with renal disease were excluded from this
analysis, due to the insufficient number of patients (<5). In
total, 146 patients (27%; 96 with type 1 VWD and 50 with
type 2 VWD) had any of these relevant comorbidities.
Patients with relevant comorbidities were more often female
(740% vs. 611%, P = 0006) and were older [58 years (11)
vs. 42 years (14), P < 0001], than patients without relevant
comorbidities. There was no difference in blood group
(614% vs. 623% blood group O, P = 0839).
VWF and FVIII levels were strongly associated with the
number of comorbidities in patients with type 1 VWD. As
the number of relevant comorbidities increased, VWF:Ag,
VWF:CB, VWF:Ab and FVIII:C increased for presence of
each additional comorbidity (Fig 6). VWF:Ag increased from
036 iu/ml [023–049] in patients without comorbidities to
044 iu/ml [029–062] in patients with one comorbidity to
067 iu/ml [039–090] in patients with two comorbidities
(P < 0001 corrected for age, sex and blood group). Similar
results were observed for VWF:CB, VWF:Ab and FVIII:C
(Fig 6).
The age-related increase of VWF and FVIII levels in type
1 VWD
In patients with type 1 VWD, age was associated with higher
VWF:Ag, VWF:CB, VWF:Ab and FVIII:C, with a respective
increase per decade of 003 iu/ml (95% CI: 001–004),
002 iu/ml (95% CI: 000–004), 004 iu/ml (95% CI: 002–
006) and 003 iu/ml (95% CI: 001–006) (Fig 7; Table SI).
After adjustment for relevant comorbidities no significant
association was observed between age and VWF:Ag, VWF:
CB, VWF:Ab or FVIII:C, respectively 001 iu/ml (95% CI:
001 to 003), 000 iu/ml (95% CI: 002 to 002), 002 iu/
ml (95% CI: 001 to 004) and 001 iu/ml (95% CI: 001
to 004) (Fig 7; Table SI). Moreover, in patients without rele-
vant comorbidities (n = 234) there was no association
between age and VWF:Ag, VWF:CB, VWF:Ab or FVIII:C,
with a difference per decade of 001 iu/ml (95% CI: 001
to 002), 000 iu/ml (95% CI: 003 to 003), 001 iu/ml
(95% CI: 002 to 004) and 001 iu/ml (95% CI: 002 to
004), respectively (Figure S2). Blood group was not a rele-
vant confounder in these analyses and was not different
between patients with or without relevant comorbidities
(663% vs. 692% blood group O, P = 0547). Nevertheless,
the age-related increase in VWF and FVIII was more pro-
nounced in patients with a non-O blood group compared to
blood group O, which was only significant for VWF:CB
[004 iu/ml vs. 002 iu/ml increase per decade (P = 0023)].
Even when we assessed the increase of VWF levels as a per-
centage of the mean VWF levels in patients with blood group
O and a non-O blood group, the age-related increase of
Fig 3. The association between diabetes mellitus and VWF and FVIII. Number of patients with and without diabetes are respectively in type 1:
n = 14 vs. n = 319, type 2: n = 6 vs. n = 197. Multiple regression outcomes in type 1 VWD corrected for; age, sex and blood group. VWF:Ag.
VWF:CB and VWF:Ab additionally corrected for hypertension. Moreover, VWF:Ag also corrected for hypercholesterolaemia. Multiple regression
outcomes in type 2 VWD corrected for; age, sex and blood group. VWF:Ag, VWF:Ab and FVIII:C additionally corrected for hypertension. More-
over, VWF:Ag, VWF:CB and FVIII:C for hypercholesterolaemia and FVIII:C for arterial thrombotic events. The association between diabetes and
VWF levels was only adjusted for other comorbidities when the other comorbidities were relevant confounders (see methods). Data presented as
boxplots with median and interquartile ranges, and 5–95 percentiles. *P < 005. **P < 001. FVIII:C, factor VIII coagulant activity; ns, not signif-
icant; VWD, von Willebrand disease; VWF:Ab, von Willebrand factor activity as measured by a monoclonal antibody assay; VWF:Ag; von Wille-
brand factor antigen; VWF:CB, von Willebrand factor collagen binding capacity.
F. Atiq et al
98 ª 2018 The Authors. British Journal of Haematology published by John Wiley & Sons Ltd.
British Journal of Haematology, 2018, 182, 93–105
VWF levels was more pronounced in patients with a non-O
blood group, which, for VWF:CB was 87% (non-O) vs.
35% (O) increase per decade (P = 0023). In both groups
the age-related increase of levels could be explained by the
presence of relevant comorbidities.
Pathophysiology of increased VWF levels
In type 1 VWD patients, no association was found between
VWFpp and the presence of relevant comorbidities, 004 iu/
ml (95% CI: 005 to 014, corrected for age, sex and blood
group). The VWFpp/VWF:Ag ratio was 123 (95% CI:
201 to 045) lower in VWD patients with relevant
comorbidities, compared to patients without comorbidities
(corrected for age, sex and blood group). No association
between FVIII:C/VWF:Ag ratio and relevant comorbidities
was found, 018 iu/ml (95% CI: 040 to 004). Also no
association was observed between VWFpp or the VWFpp/
VWF:Ag or FVIII:C/VWF:Ag ratios and comorbidities in
patients with type 2 VWD.
Fig 4. The association between cancer and VWF and FVIII. Number of patients with and without cancer are respectively in type 1: n = 15 vs.
n = 318, type 2: n = 8 vs. n = 195. Multiple regression outcomes corrected for age, sex and blood group. Data presented as boxplots with median
and interquartile ranges, and 5–95 percentiles. *P < 005. FVIII:C, factor VIII coagulant activity; ns, not significant; VWD, von Willebrand dis-
ease; VWF:Ab, von Willebrand factor activity as measured by a monoclonal antibody assay; VWF:Ag; von Willebrand factor antigen; VWF:CB,
von Willebrand factor collagen binding capacity.
Fig 5. The association between thyroid dysfunction and VWF and FVIII. Number of patients with and without hyperthyroidism are respectively
n = 5 vs n = 327. Number of patients with and without hypothyroidism are respectively n = 10 vs. n = 322. Multiple regression outcomes cor-
rected for; age, sex, blood group and hypo- or hyperthyroidism. Data presented as boxplots with median and interquartile ranges, and 5–95 per-
centiles. *P < 005. FVIII:C, factor VIII coagulant activity; ns, not significant; VWD, von Willebrand disease; VWF:Ab, von Willebrand factor
activity as measured by a monoclonal antibody assay; VWF:Ag; von Willebrand factor antigen; VWF:CB, von Willebrand factor collagen binding
capacity.
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The effect of comorbidities on bleeding phenotype
Type 1 VWD patients with comorbidities more often had a
bleeding episode in the year prior to inclusion in the study,
292% vs. 184% (P = 0030). Additionally, patients with
comorbidities had a total bleeding score of 19 (95% CI: 01–
38) higher than patients without comorbidities (corrected
for age, sex and blood group). When analysed separately,
patients with comorbidities had 06 (95% CI: 01–10) higher
bleeding score for the surgery, whereas when surgery was
excluded the bleeding score was not significantly different
(14, 95% CI: 03 to 30) (both corrected for age, sex and
blood group). In patients with type 2 VWD, we did not find
an association between comorbidities and the frequency of
bleeding in the year prior to inclusion in the study, 480%
vs. 388% (P = 0252), for either the total bleeding score
(08, 95% CI: 16 to 33), or the bleeding score for surgery
(01, 95% CI: 05 to 07) (both corrected for age, sex and
blood group).
Discussion
In this study, we demonstrate that comorbidities are associ-
ated with VWF and FVIII levels in type 1 VWD patients.
VWD type 1 patients with hypertension, diabetes mellitus,
cancer and thyroid dysfunction had higher VWF and/or
FVIII levels than VWD patients without these disorders. In
patients with type 1 VWD, these comorbidities may explain
the age-related increase of VWF and FVIII levels. Despite the
higher VWF and FVIII levels, patients with comorbidities
had more bleeding episodes in the year prior to inclusion of
the study, and had a higher total bleeding score, which was
mainly caused by more bleeding during surgery. Further-
more, VWFpp/VWF:Ag ratio was lower in patients with type
1 VWD with comorbidities, suggesting there is a slower
clearance of VWF in patients with comorbidities. In type 2
VWD, we did not find an association between comorbidities
and VWF or FVIII levels or bleeding phenotype.
In accordance with previous population studies in individu-
als without VWD (Brunner et al, 2005; Seligman et al, 2000;
Auwerda et al, 2007; Elbers et al, 2016; Franchini et al, 2013.),
we found that individuals with hypertension, diabetes, cancer
and hyperthyroidism had higher VWF and FVIII levels than
individuals without these disorders. In our study, this was
observed in both young and elderly VWD type 1 patients.
We did not expect VWD patients with hypothyroidism to
have higher VWF and FVIII levels than VWD patients with
normal thyroid function, as hypothyroidism is known to be
associated with reduced VWF levels and may even cause
acquired von Willebrand syndrome (Dalton et al, 1987; Stui-
jver et al, 2014). This also seems contradictory, because
hyperthyroidism is known to be associated with higher VWF
levels (Liu et al, 1993; Elbers et al, 2016). However, it has
been shown that VWF levels can increase after treatment
with levothyroxine (Rogers & Shane, 1983; Stuijver et al,
2014). In our study, all patients with hypothyroidism used
levothyroxine. Therefore, hypothyroidism may have resulted
in lower VWF levels in our population before they were trea-
ted, but this effect could have been reversed by treatment
with levothyroxine. In nine of 12 patients with hypothy-
roidism, VWD was clearly inherited, based on family history.
Of the remaining patients, one patient had type 2 VWD.
Therefore, in most patients acquired VWD due to hypothy-
roidism could be excluded.
Our findings suggest that the association between aging and
increase in VWF and FVIII levels in patients with type 1 VWD
may be explained by the presence of relevant comorbidities.
Fig 6. The number of comorbidities and VWF and FVIII levels in type 1 VWD. There were 236 patients with 0 relevant comorbidities, 77
patients with 1 relevant comorbidity and 18 patients with two relevant comorbidities. Only 2 patients had three relevant comorbidities and are
excluded from the figure. Data presented as boxplots with median and interquartile ranges, and 5–95 percentiles. *P < 0001, Multiple regression
outcomes corrected for age, sex and blood group. FVIII:C, factor VIII coagulant activity; VWD, von Willebrand disease; VWF:Ab, von Willebrand
factor activity as measured by a monoclonal antibody assay; VWF:Ag, von Willebrand factor antigen; VWF:CB, von Willebrand factor collagen
binding capacity.
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Fig 7. The effect of comorbidities on the age-related increase of VWF and FVIII levels in type 1 VWD. FVIII:C, factor VIII coagulant activity;
VWD, von Willebrand disease; VWF:Ab, von Willebrand factor activity as measured by a monoclonal antibody assay; VWF:Ag, von Willebrand
factor antigen; VWF:CB, von Willebrand factor collagen binding capacity.
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The age-related increase of VWF and FVIII levels was demon-
strated previously in several studies. However, many of these
reports did not take comorbidities into account (Favaloro
et al, 2005; Tofler et al, 2005; Vischer et al, 2005; Miesbach &
Berntorp, 2011; Sanders et al, 2014; Rydz et al, 2015; Borghi
et al, 2017; Abou-Ismail et al, 2018). Gill et al (1987) found
that medication use was associated with higher VWF:Ag in
VWD patients with blood group A. This could have been
caused by the comorbidities, i.e. hypertension, for which the
medication was used, as many patients (43%) used an anti-
hypertensive drug. In a well-designed study, Coppola et al
(2003) found an age-related increase of VWF:Ag in 74 healthy
centenarians and 110 healthy controls younger than 82 years
(range 21–86). However, they defined “healthy” based on the
Senieur Protocol in which some disorders, including thyroid
dysfunction, is defined as healthy (Ligthart et al, 1984). More-
over, although centenarians might not have a disorder, the
combination of reduced function in several organ could have
led to an increase of VWF or FVIII levels in a similar pattern as
in patients with relevant comorbidities. Albanez et al (2016)
found that the age-related increase of VWF and FVIII is stron-
gest in patients with non-O blood group. Also, in our popula-
tion, the age-related increase in VWF and FVIII levels seemed
to be stronger in patients with non-O blood group. However,
the association with comorbidities was independent of the
blood group. Furthermore, there was no association between
the previously reported CLEC4M and STXBP5 mutations and
the effect of comorbidities on VWF levels (data not shown)
(Sanders et al, 2015b).
In type 1 VWD, the VWFpp/VWF:Ag ratio was lower in
patients with relevant comorbidities, whereas there was no
association with VWFpp or FVIII:C/VWF:Ag ratio. This find-
ing is quite surprising, because we expected that VWF and
FVIII levels rise in patients with comorbidities due to more
endothelial VWF release. However, our results suggest that
patients with comorbidities have higher VWF and FVIII
levels due to a slower clearance of VWF, and that therefore
VWF remains for a longer period in the circulation (Eiken-
boom et al, 2013). Potentially, low-density lipoprotein recep-
tor-related protein-1 (LRP1), which has a significant role in
VWF clearance, could have an important role in understand-
ing this association, because LRP1 alterations are associated
with several disorders, including cancer, hypertension and
inflammation (Sendra et al, 2008; Gonias & Campana, 2014;
Lenting et al, 2015).
Despite the higher VWF and FVIII levels, type 1 VWD
patients with comorbidities presented with more bleeding
episodes than patients without comorbidities. In particular,
these patients experienced more perioperative bleeding. This
may be caused by the fact that patients with type 1 VWD in
whom VWF levels are normalized due to an age-related
increase of VWF, may have been incorrectly less often pro-
phylactically treated perioperatively, however we do not have
detailed information on perioperative treatment in these
individuals. Moreover, it is expected that patients with
comorbidities more often undergo surgical interventions,
such as surgical removal of tumours in patients with cancer
or tissue removal in patients with a diabetic foot. Prospective
studies are needed to further clarify the association between
comorbidities and perioperative bleeding.
The primary strength of this study is the large number of
patients with VWD that enabled us to assess the role of sev-
eral comorbidities on VWF and FVIII levels. Therefore, we
could correct the multiple regression models for various rele-
vant confounders. We also included use of relevant medica-
tion, such as anti-hypertensive drugs and statins in the
analyses. Additionally, we assessed the role of comorbidities
on bleeding phenotype.
The most important limitation of this study is that we did
not longitudinally asses VWF levels in patients, therefore we
could not assess the association between comorbidities and the
age-related increase of VWF levels intra-individually. In addi-
tion, the data on comorbidities is patient-reported. However,
we also obtained information on medication use and, in most
patients, the use of medication confirmed the presence of the
patient-reported comorbidities. Moreover, we previously eval-
uated the medical records of patients that reported arterial
thrombotic events. All patient-reported diagnosis were con-
firmed and no other arterial thrombotic events were found in
a random sample of 237 VWD patients (Sanders et al, 2013).
Furthermore, although the total sample size is large, for hyper-
and hypothyroidism the numbers of patients were small.
Therefore, for these comorbidities the analysis could poten-
tially be overfitted. Another limitation of this study is that the
bleeding phenotype was retrospectively assessed, which is less
accurate than an assessment at diagnosis, for which it was
originally developed. Furthermore, we do not have detailed
information on comorbidity-related measurements, such as
the blood pressure and HbA1c. However, this study aimed to
assess the influence of comorbidities on VWF and FVIII levels,
independent of disease control. To validate our findings a
prospective study should be performed with measurement of
VWF and FVIII levels over time in individuals who develop
comorbidities during follow-up.
In conclusion, this is the first study on the association
between comorbidities and VWF and FVIII levels in patients
with VWD. Type 1 VWD patients with hypertension, dia-
betes mellitus, cancer and thyroid dysfunction had higher
VWF and/or FVIII levels than VWD patients without these
disorders. Comorbidities may explain the age-related increase
of VWF and FVIII levels in patients with type 1 VWD.
Despite the higher VWF and FVIII levels, patients with
comorbidities had more bleeding episodes, particularly bleed-
ing during surgery.
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